Radioactive Iodine

Long-Term Risk of Second Primary Malignancies in Pediatric and Young Adult Differentiated Thyroid Cancer Survivors: A Four-Decade Real-World Study

By MedXY 08/17/2026

Pediatric and young adult survivors of differentiated thyroid cancer face a significant long-term risk of second primary malignancies, especially with radioactive iodine treatment, highlighting the need for extended surveillance and tailored therapy.

Diabetes & Endocrinology news Oncology

Detectable Antithyroglobulin Antibodies Above the Assay LOQ Signal Higher Recurrence Risk in Papillary Thyroid Carcinoma Despite Undetectable Thyroglobulin

By MedXY 06/03/2026

In papillary thyroid carcinoma treated with thyroidectomy and RAI, TgAb levels above the assay’s limit of quantification identified patients with higher long-term recurrence risk despite undetectable serum thyroglobulin.

General Surgery news Oncology

ATA Guideline Updates Reduced Thyroid Cancer Overtreatment in a 31,861-Patient South Korean Cohort

By MedXY 04/30/2026

A large South Korean cohort found ATA-guideline de-escalation reduced total thyroidectomy, RAI use, and permanent hypocalcemia in papillary thyroid carcinoma, without significant loss of 5-year disease-free survival.

Diabetes & Endocrinology news Oncology

De-escalating Management of N1b Papillary Thyroid Carcinoma: Are Total Thyroidectomy and RAI Mandatory for All?

By MedXY 12/24/2025

A multicenter study challenges the mandatory use of total thyroidectomy and radioactive iodine in all patients with lateral neck metastasis (cN1b) papillary thyroid carcinoma, suggesting that lobectomy may offer comparable oncologic outcomes in selected intermediate-risk cases.